Back to Search
Start Over
Investigating the Impact of Polypharmacy and Anticholinergic Medication Burden on Objective Cognitive Performance in Adults With Multiple Sclerosis.
- Source :
- International Journal of MS Care; Mar/Apr2024, Vol. 26 Issue 2, p81-88, 8p
- Publication Year :
- 2024
-
Abstract
- BACKGROUND: Polypharmacy, or the use of 5 or more daily medications, is common in adults with multiple sclerosis (MS), and is often due to various physical, cognitive, and emotional symptoms. However, research regarding the association between polypharmacy and cognitive outcomes in MS is sparse. Furthermore, individuals with MS often use medications with anticholinergic properties, which are commonly associated with cognitive impairment and other central nervous system adverse effects. Currently, the utility of scales measuring anticholinergic burden in MS is unknown. This study aims to investigate the relationship between polypharmacy, anticholinergic burden, and objective cognitive performance in MS. METHODS: We recruited 90 individuals with MS during routine visits at an MS specialty clinic in Kansas City. Participants completed a brief, virtual cognitive assessment and answered questions about their health. Participants provided their medication lists from which we determined polypharmacy and scores on several anticholinergic burden scales. Statistical analyses included Spearman correlations and linear regression models. RESULTS: Approximately 44% of the individuals surveyed met the criteria for polypharmacy. The number of daily medications was negatively correlated with cognitive performance (rs = -0.45, P < .001). Further, the Drug Burden Index accounted for additional variance in cognitive performance beyond that explained by age, education, MS disease duration, and comorbidities [ΔR2 = .12, F(5, 84) = 7.84, P < .001.] CONCLUSIONS: Clinicians should consider the possible negative consequences of polypharmacy when addressing cognitive concerns in MS. Anticholinergic burden scales may be valuable in this regard. Future investigations could explore behavioral and pharmacological interventions aimed at reducing polypharmacy in MS [ABSTRACT FROM AUTHOR]
- Subjects :
- PARASYMPATHOMIMETIC agents
BACLOFEN
THYROXINE
COGNITIVE testing
MULTIPLE sclerosis
DATA analysis
DISEASE duration
ACADEMIC medical centers
MEDICAL prescriptions
PREDICTION models
RESEARCH funding
HYPERLIPIDEMIA
QUESTIONNAIRES
RESEARCH evaluation
HYPERTENSION
POLYPHARMACY
DESCRIPTIVE statistics
AGE distribution
ANXIETY
ANALGESICS
ANTIDEPRESSANTS
STATISTICS
CONTENT mining
GABAPENTIN
CONFIDENCE intervals
DATA analysis software
HEALTH outcome assessment
MEDICAL care costs
REGRESSION analysis
MENTAL depression
MIGRAINE
ADULTS
Subjects
Details
- Language :
- English
- ISSN :
- 15372073
- Volume :
- 26
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- International Journal of MS Care
- Publication Type :
- Academic Journal
- Accession number :
- 176024462
- Full Text :
- https://doi.org/10.7224/1537-2073.2023-014